166 related articles for article (PubMed ID: 32483736)
1. Muramyl Tripeptide-Phosphatidyl Ethanolamine Encapsulated in Liposomes (L-MTP-PE) in the Treatment of Osteosarcoma.
Meyers PA
Adv Exp Med Biol; 2020; 1257():133-139. PubMed ID: 32483736
[TBL] [Abstract][Full Text] [Related]
2. Muramyl tripeptide-phosphatidyl ethanolamine encapsulated in liposomes (L-MTP-PE) in the treatment of osteosarcoma.
Meyers PA; Chou AJ
Adv Exp Med Biol; 2014; 804():307-21. PubMed ID: 24924182
[TBL] [Abstract][Full Text] [Related]
3. Biologic therapy for osteosarcoma using liposome-encapsulated muramyl tripeptide.
Kleinerman ES
Hematol Oncol Clin North Am; 1995 Aug; 9(4):927-38. PubMed ID: 7490249
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of liposomal muramyl tripeptide (CGP 19835A) in the treatment of relapsed osteosarcoma.
Kleinerman ES; Gano JB; Johnston DA; Benjamin RS; Jaffe N
Am J Clin Oncol; 1995 Apr; 18(2):93-9. PubMed ID: 7900714
[TBL] [Abstract][Full Text] [Related]
5. Liposomal muramyl tripeptide phosphatidylethanolamine: Targeting and activating macrophages for adjuvant treatment of osteosarcoma.
Nardin A; Lefebvre ML; Labroquère K; Faure O; Abastado JP
Curr Cancer Drug Targets; 2006 Mar; 6(2):123-33. PubMed ID: 16529542
[TBL] [Abstract][Full Text] [Related]
6. Liposomal muramyl tripeptide phosphatidyl ethanolamine: ifosfamide-containing chemotherapy in osteosarcoma.
Anderson P
Future Oncol; 2006 Jun; 2(3):333-43. PubMed ID: 16787112
[TBL] [Abstract][Full Text] [Related]
7. Liposome-encapsulated muramyl tripeptide: a new biologic response modifier for the treatment of osteosarcoma.
Kleinerman ES; Maeda M; Jaffe N
Cancer Treat Res; 1993; 62():101-7. PubMed ID: 8096724
[TBL] [Abstract][Full Text] [Related]
8. Liposomal muramyl tripeptide phosphatidyl ethanolamine: a safe and effective agent against osteosarcoma pulmonary metastases.
Mori K; Ando K; Heymann D
Expert Rev Anticancer Ther; 2008 Feb; 8(2):151-9. PubMed ID: 18279055
[TBL] [Abstract][Full Text] [Related]
9. Adjuvant therapy for osteosarcoma in dogs: results of randomized clinical trials using combined liposome-encapsulated muramyl tripeptide and cisplatin.
Kurzman ID; MacEwen EG; Rosenthal RC; Fox LE; Keller ET; Helfand SC; Vail DM; Dubielzig RR; Madewell BR; Rodriguez CO
Clin Cancer Res; 1995 Dec; 1(12):1595-601. PubMed ID: 9815961
[TBL] [Abstract][Full Text] [Related]
10. Addition of muramyl tripeptide to chemotherapy for patients with newly diagnosed metastatic osteosarcoma: a report from the Children's Oncology Group.
Chou AJ; Kleinerman ES; Krailo MD; Chen Z; Betcher DL; Healey JH; Conrad EU; Nieder ML; Weiner MA; Wells RJ; Womer RB; Meyers PA;
Cancer; 2009 Nov; 115(22):5339-48. PubMed ID: 19637348
[TBL] [Abstract][Full Text] [Related]
11. Combination therapy with ifosfamide and liposome-encapsulated muramyl tripeptide: tolerability, toxicity, and immune stimulation.
Kleinerman ES; Meyers PA; Raymond AK; Gano JB; Jia SF; Jaffe N
J Immunother Emphasis Tumor Immunol; 1995 Apr; 17(3):181-93. PubMed ID: 7613644
[TBL] [Abstract][Full Text] [Related]
12. [L-MTP-PE--a potential antineoplastic agent].
Dzierzbicka K; Gozdowska M; Kołodziejczyk AM
Postepy Hig Med Dosw; 1997; 51(2):227-36. PubMed ID: 9235567
[TBL] [Abstract][Full Text] [Related]
13. Macrophages inhibit human osteosarcoma cell growth after activation with the bacterial cell wall derivative liposomal muramyl tripeptide in combination with interferon-γ.
Pahl JH; Kwappenberg KM; Varypataki EM; Santos SJ; Kuijjer ML; Mohamed S; Wijnen JT; van Tol MJ; Cleton-Jansen AM; Egeler RM; Jiskoot W; Lankester AC; Schilham MW
J Exp Clin Cancer Res; 2014 Mar; 33(1):27. PubMed ID: 24612598
[TBL] [Abstract][Full Text] [Related]
14. Liposome-encapsulated MTP-PE: a novel biologic agent for cancer therapy.
Asano T; Kleinerman ES
J Immunother Emphasis Tumor Immunol; 1993 Nov; 14(4):286-92. PubMed ID: 8280710
[TBL] [Abstract][Full Text] [Related]
15. Current studies of liposome muramyl tripeptide (CGP 19835A lipid) therapy for metastasis in spontaneous tumors: a progress review.
MacEwen EG; Kurzman ID; Helfand S; Vail D; London C; Kisseberth W; Rosenthal RC; Fox LE; Keller ET; Obradovich J
J Drug Target; 1994; 2(5):391-6. PubMed ID: 7704483
[TBL] [Abstract][Full Text] [Related]
16. In vitro and in vivo enhancement of canine pulmonary alveolar macrophage cytotoxic activity against canine osteosarcoma cells.
Kurzman ID; Shi F; Vail DM; MacEwen EG
Cancer Biother Radiopharm; 1999 Apr; 14(2):121-8. PubMed ID: 10850295
[TBL] [Abstract][Full Text] [Related]
17. Mifamurtide for the treatment of nonmetastatic osteosarcoma.
Ando K; Mori K; Corradini N; Redini F; Heymann D
Expert Opin Pharmacother; 2011 Feb; 12(2):285-92. PubMed ID: 21226638
[TBL] [Abstract][Full Text] [Related]
18. Liposome-encapsulated muramyl tripeptide phosphatidylethanolamine (L-MTP-PE): a randomized clinical trial in dogs with mammary carcinoma.
Teske E; Rutteman GR; vd Ingh TS; van Noort R; Misdorp W
Anticancer Res; 1998; 18(2A):1015-9. PubMed ID: 9615757
[TBL] [Abstract][Full Text] [Related]
19. Comparative pharmacokinetics of free muramyl tripeptide phosphatidyl ethanolamine (MTP-PE) and liposomal MTP-PE.
Gay B; Cardot JM; Schnell C; van Hoogevest P; Gygax D
J Pharm Sci; 1993 Oct; 82(10):997-1001. PubMed ID: 8254500
[TBL] [Abstract][Full Text] [Related]
20. Mifamurtide in osteosarcoma--a practical review.
Anderson PM; Tomaras M; McConnell K
Drugs Today (Barc); 2010 May; 46(5):327-37. PubMed ID: 20517534
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
